We will generally get back to all inquiries in 24 hours
As an added bonus, Houshmand says that "peptides are safe for many patients," so there's not really any harm in trying them out
doi: 10.1016/j.cmet.2021.12.010 Summary Keywords GIP, GLP-1, obesity, weight loss, tirzepatide, GLP-1R agonists, GIP receptor agonists, Citation Zaffina I, Pelle MC, Armentaro G, Giofr F, Cassano V, Sciacqua A and Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
High consumer interest in weight management and metabolic health